All research and analysis tagged under Deep Dives.
Keytruda is the largest single oncology product in pharma history. It will lose primary patent protection in 2028. Merck's strategy to replace the revenue runs across subcutaneous formulation, label expansion, M&A, and a deep clinical pipeline. The Research Desk walks the full plan.
Deere finished fiscal 2025 with revenue down 12 percent year-over-year and net income compressed to $5.0 billion. The cycle has turned. The longer-term story is the precision agriculture platform, which now produces recurring software-like revenue and is changing the franchise's earnings durability. The Research Desk goes deep.
Lilly's revenue compounded 56% in the most recent quarter on a $30+ billion run-rate. The GLP-1 cycle is the most consequential pharmaceutical event since the statin era. The data behind the thesis.
Disney generated $10 billion of free cash flow in fiscal 2025, the first sustained recovery from the streaming-driven cash burn cycle. Direct-to-Consumer reached operating profitability. The next leg requires Parks operating leverage that is, finally, in motion.
Intel has burned $44 billion of free cash flow over four years funding the foundry pivot. The 18A node ramp is now the entire thesis. The exit options are narrower than the consensus believes.
AMZN's FY2025 revenue hit $716.9B with net income of $77.7B. AWS, advertising, and the maturing retail margin form a three-engine compounding profile that the FCF compression is hiding.
Microsoft's $50B FY2025 capex absorbed most of operating cash. The Research Desk argues the value-creation arithmetic justifies the spend, with Azure compounding revenue at 33% and operating margin at 47%.
Two of the world's three largest companies, two very different growth and margin profiles. AAPL trades at 31.3x forward, MSFT at 22.1x. The Research Desk verdict on which deserves the premium dollar today.
GE Aerospace generated $7.3 billion of free cash flow in 2025 against $45.9 billion of revenue, a 16% conversion that ranks at the top of the aerospace peer group. The CFM and GEnx engine installed base produces a multi-decade service revenue annuity that the multiple has only partially captured.
The data from three complete mining capital expenditure cycles, 2007-2012, 2014-2018, and 2020-2025, points to the same operational truth at Rio Tinto. The capex spike that began in 2024 is following the historical script with surprising fidelity, and the cash flow recovery that follows is more reliable than the bear case suggests.
Three weeks after we flagged High-NA risk, the Q1 2026 backlog print arrived. The bookings number was stronger than feared but the customer concentration deteriorated meaningfully. The thesis updates rather than reverses; ASML remains the best risk-reward in semiconductor equipment but the multiple deserves a sharper haircut.
At a $342 billion market cap and 111x forward earnings, Palantir is trading on a commercial AI deployment thesis that has only partially shown up in the financials. Pulling apart the segment economics, the contract durations, and the customer cohort behaviour produces a more nuanced picture than the bull or bear case suggests.
Revenue doubled to $4.8B in FY25, net income flipped to $497M, and the bank charter is finally producing the funding benefit bulls promised. The Research Desk goes inside the SoFi model to examine the durability of the profit inflection.
Iron ore still pays the bills. Copper builds the future. The Research Desk looks inside BHP's capital allocation across Escondida, Oak Dam, and Canadian potash to test whether the transition is priced correctly at 15x forward.
FY26 revenue reached $215.9B with operating margin at 65 percent. The Research Desk looks at three prior cycles to test whether the Physical AI narrative creates a fourth leg or marks the cycle top.
Medicare coverage changes on GLP-1s dominate the headlines. The non-obesity pipeline is where the next leg of Lilly's multiple sits.
Coco Robotics in San Jose. Lucid on robotaxis. The autonomy roadmap at Uber is no longer a slide. It is a revenue line.
Retail media is the story underneath the retail story. The scale is already there. The margin profile is not priced into a consumer staples multiple.
Keytruda revenue crossed $28 billion in 2025. The patent cliff arrives in 2028. The pipeline detail, the HIV expansion, and the ADC portfolio together suggest the revenue replacement math is already substantially solved.
Revenue at $22.1 billion, FCF at $7.3 billion, reserves of 135 million ounces, and a 14x forward multiple. The Research Desk examines the valuation gap to peers.
Revenue is down 26% from peak, but operating margin has held at 17.5% thanks to the precision platform. The Research Desk examines whether the transition sustains the 33x multiple.
Revenue passed $94 billion, operating income hit $25.6 billion, and the MedTech segment is quietly compounding at double-digit rates while the market is still processing the Kenvue separation.
Free cash flow doubled to $7.3 billion, the service backlog keeps building, and the FY25 print is the clearest signal yet that the post-spin business is a different company.
Our prior take argued the market was finally pricing the AWS capex acceleration as an investment rather than a drag. Six months later, capex has stepped again and FCF has compressed sharply. The thesis needs a meaningful update.
Caterpillar compounds free cash flow in ways peers cannot match. The current cycle is producing the kind of margin discipline and order-book visibility that historically has supported a multi-year re-rate. At 34x forward earnings, the multiple is reasonable on mid-cycle earnings power.
Tesla owns the scale economics. Rivian just put up a positive gross margin for the first time in its public history. Each company is building a different business inside the same EV category, and the comparison says one of them deserves the premium.
The Q1 MedTech data is the line item the market was not pricing. Combined with a Stelara erosion curve that is shallower than the 2024 bear case assumed, the forward-earnings arithmetic changes.
Honeywell announced a plan in early 2025 to split into three independent companies: Aerospace, Automation, and Advanced Materials. The split is structural; the implied sum-of-the-parts valuation is roughly 15-20% above the current enterprise value.
Capex collapsed from $12.1 billion in 2024 to $3.0 billion in 2025 as the Marathon Oil integration closed and the major Willow and LNG capex waves finished. Free cash flow jumped to $16.8 billion. The off-cycle is the story.
Revenue has plateaued at $84 billion for three consecutive years while free cash flow has softened from $16.5 billion to $14 billion. The pattern, across three complete consumer cycles, is unmistakable. So is the response it demands.
Revenue reaccelerated to 34% growth and AI consumption is scaling, but Databricks competition and elevated stock-based compensation have lowered our conviction.
Revenue grew 34% to $2.17 billion with 74% gross margins, and the edge network spanning 300+ cities creates a competitive advantage that hyperscalers cannot easily replicate.
Goldman's $17.2 billion in net income and 38.3% operating margins are driven by a structural role as the financial intermediary for the AI infrastructure buildout.
Azure AI services crossed an estimated $18 billion run-rate in early 2026. Copilot seat attach is accelerating. The AI monetisation curve inside Microsoft is the steepest of any software company in history.
Boeing announced Q1 deliveries and the defence business continues to quietly reset. The detail behind the number matters more than the number itself.
Zepbound supply has tripled since launch and is still constrained. The manufacturing footprint now represents one of the strongest competitive moats in large-cap pharma.
Pfizer is three years into a reset that has reshaped the pipeline, the balance sheet, and the long-term earnings profile. The market still prices the old narrative.
BHP is up 60% in a year, iron ore curbs are easing, and the copper pivot is maturing. Three cycles of data point to where the stock sits now.
ASML is the sole manufacturer of EUV lithography machines. With 200 systems in the field, High-NA ramping, and AI driving secular demand, the installed base alone is worth more than the market appreciates.
Amazon stock popped on a pair of satellite deals including a partnership with Apple. The Kuiper story has suddenly stopped looking like a moonshot.
SoFi's bank charter has transformed its funding costs, member economics, and competitive moat. At $18 billion market cap with $2.7 billion in revenue and 9 million members, the Research Desk breaks down why this is the most underappreciated fintech story in the market.
Honeywell trades at 33.9x earnings with a $149 billion market cap, a 1.9% dividend yield, and four distinct business segments — each arguably worth more separately than together. The breakup thesis is gaining momentum.
From 5.3% to 11.2% operating margin in four years. Now the company is spending $131.8 billion in a single year. This is either the best capital allocation decision in tech history or a very expensive bet on demand that may not materialise.
Revenue has recovered past the Humira patent cliff to $61.2 billion, but net income stuck at $4.2 billion exposes the gap between top-line replacement and bottom-line recovery.
Merck's 40th KEYTRUDA indication and approaching MK-0616 FDA decision tell a story about the post-patent strategy that consensus models are underestimating.
Operating income has grown sixfold since 2022. The market still thinks it is buying a retailer.
While hardware and chip stocks spent April repricing trade war exposure, Netflix had no supply chain to worry about. The real question is whether the margin transformation from 17.8% to 29.5% in three years justifies a 40x multiple.
The 2028 patent cliff is the defining event for Merck's next decade. Tulisokibart, ADCs, and subcutaneous Keytruda are the three bets management is making.
Seven consecutive earnings beats, 41% operating margins, and the largest AI infrastructure buildout in big tech. The valuation does not reflect any of it.
Datadog's revenue hit $2.8 billion growing at 25%, with AI-native monitoring products already contributing 8% of new ARR. The platform consolidation thesis is playing out faster than expected.
Post-Kenvue spin-off, J&J is a pure pharmaceutical and medtech company. Revenue hit $91.7B with a 22% profit margin. The immunology pipeline alone could be worth $20B in peak sales.
Revenue surged 38% to $65.2B in FY2025 as Mounjaro and Zepbound scaled. With manufacturing constraints easing and retatrutide data approaching, we're raising our revenue estimate to $90-100B by 2028.
The market still prices Amazon as a retailer. The financials say otherwise.
Pfizer's revenue has halved from its pandemic peak, but the oncology pipeline — anchored by a $43 billion Seagen acquisition — is the most ambitious portfolio rebuild in pharma history.
The Next Generation Air Dominance contract gives Boeing a $100B+ programme lifecycle and proof its engineering edge survives the MAX crisis — arriving just as the commercial recovery gains momentum.
Operating margins hit 11.2% in 2025, up from 2.4% in 2022. Now Amazon is spending more on infrastructure than any company in history. That tension defines the investment case.
The gross profit compression from 75% to 71% is $8 billion in forgone earnings. At $4.3 trillion, the question is whether that is the floor or the beginning.
With 79% gross margins, $1 billion in free cash flow, and a first-mover position in AI observability, Datadog is building the monitoring layer that every AI deployment needs.
With $4 billion in ARR, 78% gross margins, 120%+ net retention, and 75% of customers on 5+ modules, CrowdStrike is winning the cybersecurity platform consolidation war.
With 57.7% operating margins, $15 billion in net income, and a network moat that has defeated every fintech challenger, Mastercard at 25x forward earnings is a premium compounder at a fair price.
The world's largest healthcare company by revenue just posted a 2.7% profit margin on $447.6 billion in revenue. The Optum story is strong — but the insurance side is under pressure.
Free cash flow tripled in 2025. The market is still pricing in a distant second.
Revenue jumped 45% to $65.2 billion and FCF recovered from near-zero to $9 billion — but at 40.8x trailing earnings, has the market already priced in the miracle?
Revenue is compounding, margins are at historic highs, and the ad engine keeps beating estimates. The question is whether $70 billion in annual AI infrastructure spend is an investment or a bill that comes due.
Both companies generate enormous cash flow, but their strategies have diverged. Exxon is betting on production growth while Chevron prioritises returns. The data reveals a clear winner.
Lilly's revenue surged from $28.3 billion to $45.0 billion in two years on the back of Mounjaro and Zepbound. At 67x trailing earnings, the market is pricing perfection — and it might be right.
China generates roughly a third of ASML's revenue. A new House bill wants to cut that off. The EUV monopoly is real, but the valuation assumes a growth path that requires the China relationship to survive.
At 18x earnings, BHP is priced as a mature iron ore dividend stock. The Antamina deal, OZ Minerals integration, and Jansen potash build tell a different story.
Search, Cloud, and YouTube each independently justify a higher price. The market is selling them as a bundle.
Free cash flow fell 77% in 2025. That is not what you think it means.
Q1 2026 came in below consensus for the second consecutive quarter. The harder question is what a genuine Tesla recovery actually requires at a $1.4 trillion valuation.
The MI300 ramp drove a 15.9% Q4 earnings surprise. The harder question is whether the GPU share story holds at current margins.
Dominant platform, disciplined margins, aggressive buybacks. But at 38x earnings, the stock prices in almost everything going right.
The $91 billion capex programme is suppressing free cash flow, but the operating machinery underneath has never been stronger.
Seven consecutive earnings beats, 41% operating margins, and 13.7x EV/EBITDA. Something is mispriced.
The market prices Uber as a disruption target. The financial data and recent AV partnerships tell a different story.
Revenue hit $7.2B in 2025, up 9% year-over-year. Operating income fell 40%. At a $47B market cap, that divergence matters.
Revenue doubled. Operating margins cratered, then began recovering. In 2025, free cash flow nearly tripled. Here is what the numbers actually say.
Down 29% from its high, PLTR's fundamentals have never been stronger. The question is whether the valuation math can ever close the gap.
The only supplier of irreplaceable chip-making equipment just got 14% cheaper. The business did not.
From negative free cash flow to $9.5 billion in four years. The streaming debate is over. The real question is how to value what Netflix has become.
The most significant structural change in Amazon's business is not in the headlines. It is in the gross margin line.
Three interlocking advantages make Microsoft structurally difficult to displace, even as the AI landscape shifts the technology industry around it.
Services now generates over $85 billion annually at margins above 70 percent. Understanding what this means for Apple's long-term economics requires separating it from the hardware narrative.
Azure is growing. Profits are growing. Free cash flow is going the wrong direction. Understanding why matters more than the headline numbers.
Revenue swings 50% with crypto prices. The question is whether the infrastructure layer Coinbase is building makes each cycle more valuable than the last.
The Supercharger network, Autopilot data, and OTA software are real advantages. At 332 times earnings, the market is pricing them as if they are already fully monetized.
AWS, advertising, and fulfillment are not three separate businesses. They are three interlocking moats that make Amazon's overall position stronger than any individual piece suggests.
Revenue grew 8x in two years. Operating margins hit 60%. The question isn't whether Nvidia has a moat, it's whether that moat is durable.
Nvidia's financials have undergone a transformation with few precedents in semiconductor history. The numbers tell a story the narrative alone cannot capture.